HAS2 and triple-negative breast carcinoma: It was shown that increases in the expression of HAS2, HYAL1-2, VEGF and ABCC2 were related to worse prognosis in patients with triple-negative breast cancer (HR: 1.11, 1.14, 1.24, 1.83 and 1.09 respectively, Figure 1B).